Top Suppliers:I want be here

912999-49-6

912999-49-6 structure
912999-49-6 structure
  • Name: AT13387
  • Chemical Name: (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
  • CAS Number: 912999-49-6
  • Molecular Formula: C24H31N3O3
  • Molecular Weight: 409.521
  • Catalog: Biochemical Inhibitor Cytoskeletal Signaling HSP eg HSP90 inhibitor
  • Create Date: 2018-06-03 08:00:00
  • Modify Date: 2024-01-09 19:09:42
  • Onalespib (AT13387) is a potent inhibitor of Hsp90, with a Kd of 0.71 nM.

Name (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
Synonyms UNII-Q7Y33N57ZZ
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone
AT-13387
Methanone, [1,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]-
AT13387
2-(2,4-dihydroxy-5-isopropylbenzoyl)-5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindole
CS-0969
N-(2,4-dihydroxy-5-iso-propylbenzoyl)(5-(4-methylpiperazin-1-yl)methyl)-iso-indoline
(2,4-Dihydroxy-5-isopropylphenyl){5-[(4-methyl-1-piperazinyl)methyl]-1,3-dihydro-2H-isoindol-2-yl}methanone
Onalespib
Description Onalespib (AT13387) is a potent inhibitor of Hsp90, with a Kd of 0.71 nM.
Related Catalog
Target

HSP90:0.71 nM (Kd)

In Vitro Onalespib (Compound 35) is a potent inhibitor of Hsp90, with Kd of 0.71 nM. Onalespib shows potent antiproliferative activity in HCT116 cells, with an IC50 of 31 nM. Onalespib also strongly inhibits the proliferation of a panel of human tumor cell lines, showing IC50 of < 100 nM[1]. Onalespib exhibits cytotoxic activity against many of the PPTP cell lines, with median IC50 of 41 nM[2].
In Vivo Onalespib (60 mg/kg, ip 3 days on and 3 days off for four cycles) shows antitumor activity in nude BALB/c mice bearing early stage HCT116 human colon carcinoma xenografts[1]. Onalespib (40 or 60 mg/kg, i.p.) induces significant differences in EFS distribution compared to controls in 17% evaluable solid tumor xenografts, but in none of the ALL xenografts[2].
Cell Assay In vitro testing is performed using DIMSCAN. Cells are incubated in the presence of Onalespib for 96 hours at concentrations from 1 nM to 10 μM[2].
Animal Admin HCT116 cells are injected SC into the right hind flank of male nude BALB/c mice. Tumours are apparent 7 to 10 days later. Mice are arranged into matched groups of 12 according to tumour volume giving a group mean of approximately 100 mm[3] at initiation of dosing. Tumour volumes are measured every 2 days. Statistical significance between groups is assessed using nonparametric one-way ANOVA. Mice are given the lactate salt of Onalespib using a repeated cycle of dosing of once per day for three days, no dose for three days, once per day for three days etc., for four dosing cycles at 60 mg/kg/dose (as free base equivalents) dissolved in 17.5% hydroxypropyl-β-cyclodextrin via the IP route. Control mice receive dose vehicle only via the same route. Tolerability is assessed by recording body weight, clinical observations and survival[1].
References

[1]. Woodhead AJ, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010 Aug 26;53(16):5956-69.

[2]. Kang MH, et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8.

Density 1.2±0.1 g/cm3
Boiling Point 605.7±55.0 °C at 760 mmHg
Molecular Formula C24H31N3O3
Molecular Weight 409.521
Flash Point 320.1±31.5 °C
Exact Mass 409.236542
PSA 67.25000
LogP 1.52
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.633
Storage condition -20℃
Hazard Codes Xi
HS Code 2933990090

~92%

912999-49-6 structure

912999-49-6

Literature: ASTEX THERAPEUTICS LIMITED Patent: WO2008/44041 A1, 2008 ; Location in patent: Page/Page column 295-296 ;

~92%

912999-49-6 structure

912999-49-6

Literature: ASTEX THERAPEUTICS LIMITED Patent: US2010/152184 A1, 2010 ; Location in patent: Page/Page column 119; 120 ;

~%

912999-49-6 structure

912999-49-6

Literature: WO2008/44045 A1, ; Page/Page column 319 ; WO 2008/044045 A1

~%

912999-49-6 structure

912999-49-6

Literature: WO2008/44034 A1, ; Page/Page column 97-98 ;

~%

912999-49-6 structure

912999-49-6

Literature: Journal of Organic Chemistry, , vol. 77, # 24 p. 11296 - 11301

~%

912999-49-6 structure

912999-49-6

Literature: Journal of Organic Chemistry, , vol. 77, # 24 p. 11296 - 11301

~%

912999-49-6 structure

912999-49-6

Literature: Journal of Organic Chemistry, , vol. 77, # 24 p. 11296 - 11301

~%

912999-49-6 structure

912999-49-6

Literature: Journal of Organic Chemistry, , vol. 77, # 24 p. 11296 - 11301

~%

912999-49-6 structure

912999-49-6

Literature: Journal of Organic Chemistry, , vol. 77, # 24 p. 11296 - 11301
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%